Gedatolisib (PF-05212384): A Comprehensive Profile of a First-in-Class Pan-PI3K/mTOR Inhibitor Poised to Redefine Treatment Paradigms in Advanced Solid Tumors

Executive Summary

Gedatolisib (PF-05212384, PKI-587) is an investigational, intravenously administered, small molecule therapeutic poised to become a first-in-class dual inhibitor of the phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling pathways. Developed by Celcuity Inc., this agent is distinguished by its unique mechanism of action, which involves the potent, comprehensive, and simultaneous inhibition of all four Class I PI3K isoforms (p110α, β, γ, δ) and both critical mTOR complexes (mTORC1 and mTORC2). This complete blockade of the PI3K/AKT/mTOR (PAM) signaling cascade is designed to overcome the adaptive resistance mechanisms that have limited the efficacy of previous single-node pathway inhibitors.

The clinical development of Gedatolisib is anchored by the pivotal Phase 3 VIKTORIA-1 trial, which has yielded practice-changing results in a population with a profound unmet medical need: patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) whose disease has progressed following treatment with a CDK4/6 inhibitor. In the PIK3CA wild-type cohort, a population with historically poor outcomes, Gedatolisib in combination with palbociclib and fulvestrant demonstrated an unprecedented 76% reduction in the risk of disease progression or death, extending median progression-free survival (PFS) to 9.3 months compared to 2.0 months with fulvestrant alone.

This remarkable efficacy is complemented by a highly favorable safety and tolerability profile. Notably, Gedatolisib is associated with low rates of severe hyperglycemia and stomatitis, common dose-limiting toxicities for this class of agents. The treatment discontinuation rate due to adverse events in the VIKTORIA-1 trial was exceptionally low (<4%), a key differentiator that enables sustained therapy and maximization of clinical benefit.

Recognizing its transformative potential, the U.S. Food and Drug Administration (FDA) has granted Gedatolisib Fast Track and Breakthrough Therapy designations and has accepted its New Drug Application (NDA) for review under the Real-Time Oncology Review (RTOR) program, signaling an accelerated path to potential approval. With promising early data also emerging in other malignancies, including metastatic castration-resistant prostate cancer (mCRPC), Gedatolisib represents a significant therapeutic advance, with the potential to establish a new standard of care and fundamentally alter the treatment landscape for a broad spectrum of solid tumors driven by PAM pathway dysregulation.

Pharmacological Profile of Gedatolisib

The therapeutic potential of Gedatolisib is rooted in its distinct chemical structure and a precisely engineered mechanism of action designed for comprehensive and durable inhibition of one of cancer's most critical signaling networks. A thorough examination of its pharmacological properties provides the foundational rationale for its clinical development and observed efficacy.

Chemical Identity and Physicochemical Properties

Gedatolisib is a synthetic organic compound classified as a small molecule therapeutic.[1] Its definitive chemical formula is

C32​H41​N9​O4​, corresponding to an average molecular weight of approximately 615.74 g/mol and a monoisotopic mass of 615.3282 g/mol.[2] It is identified globally by its Chemical Abstracts Service (CAS) Registry Number, 1197160-78-3, and is cataloged in the DrugBank database under the accession number DB11896.[1]

During its development, the compound has been referred to by several synonyms and code names, most notably the Pfizer designation PF-05212384 and the earlier identifier PKI-587.[1] The formal International Union of Pure and Applied Chemistry (IUPAC) name for the molecule is 1-phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea.[5] Chemically, it belongs to the class of 1-benzoylpiperidines, characterized by a piperidine ring substituted at the 1-position with a benzoyl group.[2]

Physically, Gedatolisib presents as an off-white solid.[7] Its solubility profile is a critical determinant of its formulation and administration route; it is characterized as being insoluble in water and ethanol but is soluble in dimethyl sulfoxide (DMSO), particularly with gentle warming.[7] An analysis of its molecular properties against Lipinski's Rule of Five, a guideline for predicting oral bioavailability, reveals two violations: a molecular weight greater than 500 Da and more than 10 hydrogen bond acceptors (13 total).[4] These characteristics are often associated with poor membrane permeability and low oral absorption. This physicochemical profile provides a strong scientific basis for the selection of an intravenous route of administration for Gedatolisib.[1] Intravenous delivery bypasses the gastrointestinal tract, ensuring 100% bioavailability and leading to more predictable and consistent pharmacokinetic profiles, which is particularly advantageous for a potent kinase inhibitor with a narrow therapeutic window.

Table 1: Gedatolisib Identification and Chemical Properties

Property	Value	Source(s)
Generic Name	Gedatolisib	1
DrugBank ID	DB11896	2
Type	Small Molecule	1
Developer	Celcuity Inc. (licensed from Pfizer)	11
Synonyms	PF-05212384, PKI-587	1
CAS Number	1197160-78-3	1
Chemical Formula	C32​H41​N9​O4​	1
Molecular Weight	615.74 g/mol	4
IUPAC Name	1-phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea	5
Administration Route	Intravenous	1
Solubility	Insoluble in water; Soluble in DMSO	7

Mechanism of Action: A Comprehensive PI3K/AKT/mTOR (PAM) Pathway Blockade

Gedatolisib is a potent and reversible dual inhibitor that simultaneously targets two of the most critical regulatory nodes within the PI3K/AKT/mTOR (PAM) signaling pathway.[1] This pathway is a central command-and-control system for fundamental cellular processes, including growth, proliferation, survival, and metabolism. Its frequent dysregulation through genetic mutations or aberrant activation is a well-established driver of oncogenesis and therapeutic resistance across a multitude of human cancers.[5]

The inhibitory activity of Gedatolisib is characterized by its breadth and potency. It functions as a pan-Class I PI3K inhibitor, demonstrating robust, low-nanomolar activity against all four of the Class I catalytic subunit isoforms: p110α (PI3Kα), p110β (PI3Kβ), p110γ (PI3Kγ), and p110δ (PI3Kδ).[16] In cell-free assays, its half-maximal inhibitory concentration (

IC50​) values are exceptionally low, measured at 0.4 nM for PI3Kα, 6.0 nM for PI3Kβ, 5.4 nM for PI3Kγ, and 6.0 nM for PI3Kδ.[3] This inhibitory profile extends to the most common oncogenic mutations of PI3Kα, such as H1047R and E545K, against which it maintains an

IC50​ of 0.6 nM.[7]

Concurrently, Gedatolisib is a highly potent inhibitor of the mTOR kinase, with a reported IC50​ of 1.6 nM.[3] A key mechanistic feature that distinguishes Gedatolisib from many other mTOR-targeting agents is its equal efficacy in inhibiting both of the distinct multi-protein complexes in which mTOR functions: mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2).[15]

This dual, comprehensive blockade of both PI3K and mTOR represents a deliberate and rational therapeutic strategy designed to overcome the known limitations of more selective inhibitors. There are three core principles underlying this approach:

1. Prevention of Isoform Switching: Targeting a single PI3K isoform, such as PI3Kα, can lead to the compensatory upregulation and activation of other isoforms (e.g., PI3Kβ) as an adaptive resistance mechanism.[15] By potently inhibiting all four Class I isoforms, Gedatolisib is designed to preemptively close this escape route, thereby preventing the confounding effects of isoform interaction and reducing the likelihood of acquired resistance.[16]
2. Abrogation of Feedback Loop Activation: The PAM pathway is regulated by a complex series of feedback loops. Specifically, mTORC1 activity normally suppresses signaling from growth factor receptors. Inhibition of mTORC1 alone (e.g., with everolimus) can relieve this negative feedback, leading to the paradoxical hyperactivation of PI3K and its downstream effector AKT, which is in turn activated by mTORC2.[15] By simultaneously inhibiting PI3K (upstream of AKT) and both mTORC1 and mTORC2 (downstream and parallel to AKT), Gedatolisib imposes a more complete and durable shutdown of the entire signaling axis.[16]
3. Broad Applicability Across Mutational Contexts: The reliance of isoform-specific inhibitors like alpelisib on the presence of activating PIK3CA mutations limits their utility. In contrast, Gedatolisib's pan-inhibitor mechanism allows it to address oncogenic signaling driven by a wider array of genetic alterations, such as PTEN loss (which often signals through PI3Kβ) or other upstream receptor tyrosine kinase activations. This mechanistic breadth provides a strong rationale for its efficacy in tumors that are both PIK3CA-mutant and PIK3CA-wild-type. The profound clinical activity observed in the PIK3CA wild-type cohort of the VIKTORIA-1 trial serves as powerful clinical validation of this foundational hypothesis.[19]

Pharmacodynamics and Preclinical Evidence

The mechanistic rationale for Gedatolisib is strongly supported by a body of preclinical evidence demonstrating its potent biological activity. In vitro, Gedatolisib effectively inhibits the proliferation of various cancer cell lines. For instance, in the MDA-361 (breast cancer) and PC3-MM2 (prostate cancer) cell lines, it demonstrated IC50​ values for growth inhibition of 4.0 nM and 13.1 nM, respectively.[7] This anti-proliferative effect is accompanied by clear evidence of on-target pathway modulation; treatment with Gedatolisib leads to a marked suppression of the phosphorylation of key downstream effectors, including AKT, GSK3 kinase, and PRAS40, confirming its ability to disrupt the PAM signaling cascade within the cellular context.[7]

Comparative preclinical studies have consistently highlighted the superiority of Gedatolisib's comprehensive blockade strategy. In head-to-head assessments against single-node PAM inhibitors—such as the PI3Kα-specific alpelisib, the pan-AKT inhibitor capivasertib, and the mTORC1-specific everolimus—Gedatolisib exerted significantly greater growth-inhibitory effects in models of gynecologic and breast cancer.[15] This superior activity extended to the inhibition of critical metabolic functions controlled by the PAM pathway, including cellular glucose consumption and lactate production, suggesting a more profound disruption of the metabolic reprogramming that fuels cancer cell growth.[21]

In vivo, Gedatolisib has demonstrated potent anti-tumor efficacy across a variety of xenograft models, including those derived from H1975, BT474, HCT116, and U87MG cell lines.[7] In a particularly compelling experiment using a staged MDA-361 xenograft model, intravenous administration of Gedatolisib at 20 mg/kg on an intermittent schedule (days 1, 5, and 9) was sufficient to cause the regression of large, established tumors (approx. 900 mm³).[7]

However, it is important to note the context-dependent nature of preclinical findings. One study investigating Gedatolisib in a preclinical model of triple-negative breast cancer (TNBC) metastasis reported that the drug, either alone or in combination with chemotherapy, failed to reliably reduce the burden of disseminated tumor cells (DTCs) or prevent the formation of metastases.[3] This result does not contradict the positive clinical data in HR+ breast cancer but rather underscores a critical principle of drug development: the predictive value of a preclinical model is highly dependent on how well it recapitulates the specific biological dependencies of the targeted human disease. The distinct biology of TNBC compared to HR+ breast cancer likely accounts for this discrepancy, reinforcing that while preclinical data provides essential mechanistic support, definitive evidence of therapeutic value must be established in well-designed clinical trials targeting appropriate patient populations.

Clinical Development Program

The clinical evaluation of Gedatolisib has been extensive and strategic, evolving from broad, early-phase exploration across multiple tumor types to a focused, late-stage program designed to establish its role as a cornerstone therapy in major oncological indications. The program reflects a deep understanding of the PAM pathway's role in cancer and a commitment to addressing areas of significant unmet medical need.

Overview of Investigational Indications

Reflecting the ubiquitous role of PAM pathway dysregulation in malignancy, Gedatolisib has been studied in a wide array of solid tumors.[1] The maximum phase of clinical development reached is Phase 3, signifying its progression to pivotal, registration-enabling studies.[1] Early- and mid-stage clinical trials have enrolled patients with a diverse range of cancers, including Breast Cancer, Endometrial Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), and Prostate Cancer.[1] While development was discontinued for some indications such as acute myeloid leukemia and colorectal cancer, the program has strategically prioritized diseases with the strongest biological rationale and largest unmet need, most notably breast and prostate cancer.[12]

The Pivotal VIKTORIA Program in HR+/HER2- Advanced Breast Cancer

The centerpiece of Gedatolisib's clinical development is the VIKTORIA program, a pair of large-scale, multinational Phase 3 trials meticulously designed to define its efficacy and safety in HR+/HER2- advanced breast cancer (ABC), the most common subtype of the disease.

• VIKTORIA-1 (NCT05501886): This is the pivotal registration trial for Gedatolisib in the second-line and beyond setting.[10] It is an open-label, randomized study specifically for patients with HR+/HER2- ABC whose disease has progressed during or after treatment with a combination of a CDK4/6 inhibitor and a non-steroidal aromatase inhibitor. The trial's innovative design stratifies the patient population based on the tumor's PIK3CA mutational status, allowing for a direct assessment of Gedatolisib's efficacy in both contexts.[25]
• In the PIK3CA wild-type cohort, patients are randomized 1:1:1 to one of three arms:

1. Triplet Therapy: Gedatolisib + palbociclib + fulvestrant
2. Doublet Therapy: Gedatolisib + fulvestrant
3. Control: Fulvestrant monotherapy.[27]

• In the PIK3CA-mutant cohort, patients are randomized 1:1:1 to:

1. Triplet Therapy: Gedatolisib + palbociclib + fulvestrant
2. Standard of Care: Alpelisib + fulvestrant
3. Doublet Therapy: Gedatolisib + fulvestrant.[26]

• VIKTORIA-2: This Phase 3 trial is designed to move Gedatolisib into an earlier line of therapy.[24] It evaluates Gedatolisib as a first-line treatment for patients with HR+/HER2- ABC who are considered to have endocrine-resistant disease (defined as relapse during or within 12 months of completing adjuvant endocrine therapy). In this study, patients are randomized to receive either the investigational regimen of Gedatolisib plus a CDK4/6 inhibitor (investigator's choice of palbociclib or ribociclib) and fulvestrant, or the control regimen of a CDK4/6 inhibitor and fulvestrant.[28]

The dual VIKTORIA trials represent a highly sophisticated and commercially astute development strategy. They are not merely confirmatory but are designed to capture two distinct and large market segments within HR+/HER2- ABC. VIKTORIA-1 targets the rapidly growing population of patients who have failed first-line CDK4/6 inhibitors, an area where subsequent therapies offer limited benefit. VIKTORIA-2 aims to establish a new, more effective standard of care for high-risk patients in the first-line setting. Success across this program would position Gedatolisib as a foundational PAM pathway inhibitor throughout the HR+/HER2- ABC treatment continuum.

Exploratory Trials in Other Malignancies

Beyond breast cancer, Celcuity is actively investigating Gedatolisib in other solid tumors where PAM pathway inhibition is a rational therapeutic strategy.

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Phase 1/2 trial (NCT06190899) is evaluating Gedatolisib in combination with the potent androgen receptor (AR) inhibitor darolutamide.[24] This trial targets patients with mCRPC who have already progressed on a prior next-generation AR signaling inhibitor. The scientific basis for this combination is the well-documented reciprocal feedback and crosstalk between the AR and PAM signaling pathways, where inhibition of one can lead to the compensatory activation of the other. Simultaneous blockade of both pathways is therefore hypothesized to produce synergistic anti-tumor activity.[31]
• HER2-Positive Breast Cancer: A Phase 2 trial (NCT03698383) has been completed, which evaluated the combination of Gedatolisib and the anti-HER2 antibody trastuzumab in heavily pretreated patients with metastatic HER2+ breast cancer whose tumors harbored PIK3CA mutations.[29]
• Other Solid Tumors: The broad potential of Gedatolisib was initially explored in several "basket" trials. A Phase 1 study (NCT03065062) investigated Gedatolisib plus the CDK4/6 inhibitor palbociclib in patients with advanced squamous cell lung cancer, pancreatic cancer, and head and neck cancer.[24] Another completed Phase 1 trial (NCT03243331) assessed its safety in combination with an antibody-drug conjugate (PTK7-ADC) in patients with metastatic triple-negative breast cancer.[2]

Table 2: Summary of Key Clinical Trials for Gedatolisib

Trial Identifier	Trial Name/Acronym	Phase	Condition(s)	Intervention(s)	Status
NCT05501886	VIKTORIA-1	3	HR+/HER2- Advanced Breast Cancer (post-CDK4/6i)	Gedatolisib + Fulvestrant +/- Palbociclib	Active 24
N/A	VIKTORIA-2	3	HR+/HER2- Advanced Breast Cancer (1st Line, Endocrine Resistant)	Gedatolisib + CDK4/6i + Fulvestrant	Active 24
NCT06190899	CELC-G-201	1/2	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Gedatolisib + Darolutamide	Active 24
NCT03698383	N/A	2	HER2+ Metastatic Breast Cancer (PIK3CA-mutant)	Gedatolisib + Trastuzumab	Unknown Status 32
NCT03065062	N/A	1	Advanced Solid Tumors (Sq. Lung, Pancreatic, H&N)	Gedatolisib + Palbociclib	Temporarily Closed to Accrual 24
NCT03243331	N/A	1	Metastatic Triple-Negative Breast Cancer	Gedatolisib + PTK7-ADC	Completed 34
NCT02626507	N/A	1b	ER+/HER2- Breast Cancer (Neoadjuvant)	Gedatolisib + Palbociclib + Fulvestrant	Completed 35
NCT01920061	N/A	1	Advanced Solid Tumors	Gedatolisib + Docetaxel / Cisplatin / Dacomitinib	Completed 36

Efficacy and Safety Analysis from Key Clinical Trials

The clinical value of Gedatolisib is defined by the robust efficacy and favorable safety data generated from its comprehensive trial program. The results from the pivotal VIKTORIA-1 study, in particular, represent a landmark achievement in the treatment of advanced breast cancer.

The VIKTORIA-1 Trial: Landmark Efficacy in Post-CDK4/6i HR+/HER2- Breast Cancer

Celcuity has reported topline results from a pre-planned interim analysis of the PIK3CA wild-type cohort of the VIKTORIA-1 trial, and the findings are exceptionally strong and clinically transformative.[19] Both Gedatolisib-containing regimens met the primary endpoint, demonstrating statistically significant and clinically meaningful improvements in progression-free survival (PFS), as determined by Blinded Independent Central Review (BICR), compared to fulvestrant monotherapy.[37]

• Triplet Regimen (Gedatolisib + Palbociclib + Fulvestrant): This combination yielded a median PFS of 9.3 months, compared to just 2.0 months for patients receiving fulvestrant alone.[19] This outcome translates to a 76% reduction in the risk of disease progression or death, with a hazard ratio (HR) of 0.24 (95% Confidence Interval [CI]: 0.17–0.35; p<0.0001).[19]
• Doublet Regimen (Gedatolisib + Fulvestrant): The doublet combination also demonstrated profound efficacy, achieving a median PFS of 7.4 months versus 2.0 months for the control arm.[19] This corresponds to a 67% reduction in the risk of disease progression or death, with an HR of 0.33 (95% CI: 0.24–0.48; p<0.0001).[19]

These results are not merely incremental; they are paradigm-shifting for a patient population with a dire prognosis. Patients with HR+/HER2- ABC who progress on first-line CDK4/6 inhibitor therapy, particularly those with PIK3CA wild-type tumors, have very few effective treatment options. Subsequent endocrine-based therapies typically offer a median PFS of only 2 to 4 months.[18] The VIKTORIA-1 data, showing an incremental PFS benefit of 7.3 months for the triplet and 5.4 months for the doublet over standard therapy, represent a monumental advance. The hazard ratio of 0.24 achieved by the triplet regimen has been described as the lowest ever reported in a Phase 3 trial for this patient population, positioning Gedatolisib to establish an entirely new standard of care upon its potential approval.[18]

Table 3: Key Efficacy Outcomes from the Phase 3 VIKTORIA-1 Trial (PIK3CA Wild-Type Cohort)

Treatment Arm	Median PFS (months)	95% CI for mPFS	Hazard Ratio (HR) vs. Fulvestrant	95% CI for HR	p-value
Gedatolisib Triplet	9.3	7.2–16.6	0.24	0.17–0.35	<0.0001
Gedatolisib Doublet	7.4	5.5–9.9	0.33	0.24–0.48	<0.0001
Fulvestrant Monotherapy	2.0	1.8–2.3	N/A	N/A	N/A
Data sourced from 19

Safety and Tolerability Profile: A Key Differentiator

The clinical utility of a therapeutic agent is determined by the balance of its efficacy and tolerability. In this regard, Gedatolisib has demonstrated a highly favorable and manageable safety profile that sets it apart from other inhibitors of the PAM pathway.[37]

In a Phase 1b study that established the dose for the VIKTORIA-1 trial, the most frequently reported Grade 3-4 treatment-related adverse events (TRAEs) for the triplet combination were hematologic and dermatologic, including neutropenia (63%), stomatitis (inflammation of the mouth, 27%), and rash (20%).[41] These are known on-target effects of PI3K and mTOR inhibition and were considered manageable with standard supportive care.

Critically, the incidence of severe hyperglycemia, a common and often dose-limiting toxicity for this drug class, was remarkably low. Grade 3-4 hyperglycemia was reported in only 6% of participants in the Phase 1b study.[41] This favorable metabolic profile is a significant advantage over other PAM inhibitors, which can be associated with much higher rates of severe hyperglycemia, often requiring dose modifications or discontinuation.

The most compelling evidence of Gedatolisib's excellent tolerability comes from the pivotal VIKTORIA-1 trial, where the treatment discontinuation rate due to adverse events was less than 4% for both the triplet and doublet regimens.[18] This rate is not only lower than what was observed in the earlier Phase 1b study but is also reported to be lower than that of any currently approved combination therapy in a Phase 3 trial for HR+/HER2- ABC.[37] This exceptionally low discontinuation rate is a powerful testament to the drug's therapeutic index. It indicates that patients are able to remain on this highly effective therapy for extended periods, allowing them to derive the maximum possible clinical benefit. This superior safety profile is a major competitive advantage and a key driver of Gedatolisib's potential for widespread clinical adoption.

Preliminary Efficacy Signals in Other Cancers

While the primary focus is on breast cancer, promising signals of activity have emerged from studies in other malignancies.

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): In the Phase 1 portion of the ongoing trial combining Gedatolisib with darolutamide, preliminary data from 36 patients revealed a 6-month radiographic PFS (rPFS) rate of 66%.[29] This result is considered highly encouraging, as it compares favorably to the historical efficacy of androgen receptor inhibitors used as monotherapy in this treatment setting.[29]
• HER2-Positive Breast Cancer: In a Phase 2 study of heavily pretreated patients with metastatic HER2+ breast cancer whose tumors harbored PIK3CA mutations, the combination of Gedatolisib and trastuzumab produced an Overall Response Rate (ORR) of 43% and a median PFS of 6.0 months.[29] This level of activity in a refractory patient population suggests a potential role for Gedatolisib in overcoming resistance to HER2-directed therapies.

Regulatory and Commercial Landscape

The transition of Gedatolisib from a promising clinical candidate to a potential standard-of-care therapy is being shaped by a strategic regulatory approach, a strong intellectual property foundation, and a clear corporate vision.

U.S. FDA Regulatory Pathway

The U.S. Food and Drug Administration (FDA) has recognized the significant potential of Gedatolisib through the granting of multiple special designations, which are intended to expedite the development and review of drugs that address serious conditions and fill an unmet medical need.

• Fast Track Designation: Gedatolisib was granted Fast Track designation in January 2022 for the treatment of patients with HR+/HER2- metastatic breast cancer whose disease has progressed during or after CDK4/6 therapy.[43] This designation facilitates more frequent interactions with the FDA to support an efficient development program.
• Breakthrough Therapy Designation: Based on compelling preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over available therapies, the FDA also granted Gedatolisib Breakthrough Therapy designation.[26] This provides all the features of the Fast Track program, plus more intensive FDA guidance on an efficient drug development program.
• Real-Time Oncology Review (RTOR): Following the announcement of the positive topline results from the VIKTORIA-1 trial, the FDA agreed to accept the New Drug Application (NDA) for Gedatolisib for review under its RTOR program.[26] The RTOR program allows the FDA to review key sections of the NDA before the formal submission of the complete application. This parallel review process can significantly shorten the time from submission to a final regulatory decision.

This trio of designations represents the FDA's strongest acknowledgment of a drug's potential clinical importance. The acceptance into the RTOR program, in particular, signals that the agency views the VIKTORIA-1 data as highly compelling and recognizes the urgent need for better therapies in this patient population. Celcuity plans to complete its rolling NDA submission to the FDA in the fourth quarter of 2025, suggesting a potential approval on an accelerated timeline.[12]

European Regulatory Context and Outlook

While the provided documentation does not indicate that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for Gedatolisib, the regulatory environment in the European Union appears favorable for novel PAM pathway inhibitors.[16] The EMA has recently authorized other targeted agents for HR+ breast cancer that modulate this pathway, including the AKT inhibitor capivasertib (Truqap) and the PI3Kα inhibitor inavolisib (Itovebi).[46]

These recent approvals establish a clear regulatory precedent and demonstrate the EMA's acceptance of the PAM pathway as a valid and important therapeutic target in breast cancer. Celcuity's corporate communications have identified the EMA as a target regulatory body for future submissions.[50] Given the strength and magnitude of the VIKTORIA-1 data, a future MAA submission for Gedatolisib would be expected to receive serious consideration, suggesting a high probability of success in securing marketing authorization in the EU.

Corporate and Intellectual Property Overview

Gedatolisib is the lead therapeutic candidate for Celcuity Inc., a clinical-stage biotechnology company based in Minneapolis that is focused on the development of targeted cancer therapies.[11] The compound, originally known as PF-05212384, was discovered and initially developed by Wyeth and later Pfizer.[12] In April 2021, Celcuity acquired the exclusive global development and commercialization rights to Gedatolisib from Pfizer.[53] Celcuity's interest in the asset was driven by insights from its proprietary CELsignia platform technology, which identified Gedatolisib as having a superior ability to inhibit PI3K-driven signaling compared to other agents evaluated.[53]

Celcuity has established a robust intellectual property portfolio to protect its lead asset. The company holds multiple patents covering Gedatolisib's composition of matter and various formulations. Most significantly, in July 2025, the U.S. Patent and Trademark Office issued a new patent (U.S. Patent No. 12,350,276) specifically covering the clinical dosing regimen of Gedatolisib in ER+/HER2- breast cancer patients. This key patent extends Celcuity's market exclusivity for Gedatolisib in the United States into 2042, providing a long and secure commercial runway post-approval, protected from generic competition.[11]

Comparative Analysis and Strategic Positioning

Gedatolisib's value proposition is best understood by contextualizing its unique attributes against the landscape of existing and other investigational therapies targeting the PAM pathway. Its differentiation is evident in its mechanism, clinical efficacy, and safety profile.

Differentiation from Single-Node PAM Pathway Inhibitors

The first generation of approved PAM pathway inhibitors for breast cancer includes the PI3Kα-specific inhibitor alpelisib and the mTORC1 inhibitor everolimus. While these agents established the clinical validity of targeting the pathway, their benefits have been modest and often accompanied by significant toxicities and the rapid development of resistance.

Numerous preclinical studies have directly compared Gedatolisib to these single-node inhibitors, as well as the investigational AKT inhibitor capivasertib.[15] The results of these studies are consistent and compelling:

• Superior Potency and Efficacy: Gedatolisib consistently demonstrates superior potency and efficacy in inducing both anti-proliferative (cytostatic) and cell-killing (cytotoxic) effects in breast and gynecologic cancer models.[15]
• Activity Independent of Mutational Status: A critical finding is that Gedatolisib's superior activity is observed regardless of the underlying PAM pathway mutational status of the cancer cells.[15] This contrasts sharply with alpelisib, whose efficacy is largely restricted to tumors harboring activating PIK3CA mutations.

Gedatolisib represents a mechanistically advanced, second-generation approach to PAM pathway inhibition. Its ability to comprehensively block multiple nodes simultaneously appears to successfully overcome the primary limitations of its predecessors. The landmark success of Gedatolisib in the PIK3CA wild-type cohort of the VIKTORIA-1 trial provides the ultimate clinical validation of this mechanistic superiority, demonstrating profound efficacy in a patient population where a PI3Kα-specific inhibitor would not be indicated.

Positioning within the Dual PI3K/mTOR Inhibitor Class

The therapeutic concept of dual PI3K/mTOR inhibition has been pursued for over a decade, with several molecules entering clinical development. This class includes compounds such as BEZ235 (dactolisib), samotolisib, and bimiralisib.[55] However, translating this concept into a clinically successful drug has proven to be exceptionally challenging. Many of these earlier candidates were hampered by an unfavorable therapeutic index, exhibiting either insufficient efficacy at tolerable doses or unacceptable toxicity at effective doses. Consequently, many have been discontinued for certain indications or have failed to advance to late-stage development.[12]

Gedatolisib is the first and only dual PI3K/mTOR inhibitor to report unequivocally positive, practice-changing results from a large, randomized Phase 3 trial.[19] Furthermore, its NDA is the first for any drug in this class to be accepted for review by the FDA.[26] Gedatolisib's success in the VIKTORIA-1 trial, which demonstrated both profound efficacy and excellent tolerability, marks a significant breakthrough for the entire class. It is therefore positioned not merely as another agent in the category, but as the undisputed class leader, poised to be the first to achieve regulatory approval and establish the clinical utility of comprehensive PAM pathway blockade.

Table 4: Comparative Profile of Selected PAM Pathway Inhibitors

Drug Name (Generic)	Target(s)	Highest Development Phase / Approval Status	Key Indication (Breast Cancer)	Key Differentiating Feature	Noteworthy Class-Related Toxicities
Gedatolisib	Pan-PI3K + mTORC1/2	Phase 3 / NDA Submitted	HR+/HER2- ABC, post-CDK4/6i	Efficacy in PIK3CA-WT; Favorable safety profile; IV admin	Stomatitis, Rash, Neutropenia, low rate of severe Hyperglycemia
Alpelisib	PI3Kα	Approved	HR+/HER2- ABC, PIK3CA-mutant	PIK3CA mutation-specific	Hyperglycemia, Rash, Diarrhea
Everolimus	mTORC1	Approved	HR+/HER2- ABC	Established but modest benefit	Stomatitis, Pneumonitis, Hyperglycemia
Capivasertib	Pan-AKT	Approved (EU/other)	HR+/HER2- ABC, PIK3CA/AKT1/PTEN-altered	Targets AKT node	Diarrhea, Rash, Hyperglycemia
Dactolisib (BEZ235)	Pan-PI3K + mTOR	Phase 1/2 (Discontinued for some tumors)	N/A	Early development, oral	N/A

Conclusion and Future Directions

Conclusion

Gedatolisib has emerged as a highly potent, first-in-class, dual pan-PI3K and mTORC1/2 inhibitor that has unequivocally demonstrated its potential to transform the treatment of advanced solid tumors. The results from the pivotal Phase 3 VIKTORIA-1 trial are nothing short of practice-changing, showing an unprecedented improvement in progression-free survival for patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer who have progressed on prior CDK4/6 inhibitor therapy. This landmark achievement addresses a large and growing patient population with a significant unmet medical need.

The drug's unique mechanism of comprehensive PAM pathway blockade appears to be the key to its success, allowing it to overcome the adaptive resistance mechanisms and dose-limiting toxicities that have challenged previous generations of more selective PAM pathway inhibitors. This is further substantiated by its highly favorable safety profile, characterized by a remarkably low rate of treatment discontinuation due to adverse events. With an accelerated regulatory pathway established with the U.S. FDA and a strong intellectual property position extending into the 2040s, Gedatolisib is firmly positioned to become a new standard of care and a cornerstone therapy in oncology.

Future Directions and Unanswered Questions

While the current data are compelling, the clinical story of Gedatolisib is still unfolding, with several key developments on the horizon.

• The most immediate and highly anticipated data will be the results from the VIKTORIA-1 PIK3CA-mutant cohort, which are expected by the end of 2025.[38] Positive results in this cohort, particularly a demonstration of superiority over the current standard of care (alpelisib), would solidify Gedatolisib's role as the optimal PAM pathway inhibitor for all patients with HR+/HER2- ABC, regardless of PIK3CA mutational status.
• The outcomes of the VIKTORIA-2 trial will be critical in determining Gedatolisib's potential in the first-line setting for high-risk, endocrine-resistant patients.[28] Success in this trial would significantly expand its market potential and establish its utility earlier in the treatment continuum.
• Continued development in metastatic castration-resistant prostate cancer, based on the encouraging early rPFS data, represents a significant opportunity for label expansion into another major solid tumor type.[29]

Looking further ahead, long-term questions will focus on the optimal sequencing of Gedatolisib with other therapies, the identification of novel biomarkers beyond PIK3CA status that may predict response or resistance, and the exploration of new rational combination strategies to further enhance its anti-tumor activity. The successful journey of Gedatolisib, from a licensed asset to a potential blockbuster therapeutic, exemplifies a well-executed clinical development strategy rooted in strong scientific rationale and targeted precisely at an area of profound clinical need.

Works cited

1. Gedatolisib | C32H41N9O4 | CID 44516953 - PubChem, accessed September 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Gedatolisib
2. Gedatolisib: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 25, 2025, https://go.drugbank.com/drugs/DB11896
3. Gedatolisib | PKI-587 | PF-05212384 | CAS#1196160-78-3 | PI3K and mTOR inhibitor, accessed September 25, 2025, https://www.medkoo.com/products/4522
4. Compound: GEDATOLISIB (CHEMBL592445) - ChEMBL - EMBL-EBI, accessed September 25, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL592445
5. Gedatolisib - Wikipedia, accessed September 25, 2025, https://en.wikipedia.org/wiki/Gedatolisib
6. gedatolisib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 25, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940
7. PF-05212384 | 1197160-78-3 - ChemicalBook, accessed September 25, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32500950.htm
8. CAS 1197160-78-3 Gedatolisib (PF-05212384, PKI-587) - BOC Sciences, accessed September 25, 2025, https://www.bocsci.com/product/gedatolisib-pf-05212384-pki-587-cas-1197160-78-3-457469.html
9. Definition of gedatolisib - NCI Drug Dictionary, accessed September 25, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gedatolisib
10. Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy - Yale Medicine, accessed September 25, 2025, https://www.yalemedicine.org/clinical-trials/gedatolisib-plus-fulvestrant-with-or-without-palbociclib-vs-standard-of-care-for-the-treatment-of-pa
11. Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 - BioSpace, accessed September 25, 2025, https://www.biospace.com/press-releases/celcuity-announces-issuance-of-new-patent-for-gedatolisib-that-extends-patent-exclusivity-into-2042
12. Gedatolisib - Celcuity - AdisInsight - Springer, accessed September 25, 2025, https://adisinsight.springer.com/drugs/800030590
13. Gedatolisib (PKI-587) | PI3K/mTOR Inhibitor | AmBeed.com, accessed September 25, 2025, https://www.ambeed.com/products/gedatolisib.html
14. Gedatolisib (PF-05212384) - Pfizer, accessed September 25, 2025, https://cdn.pfizer.com/pfizercom/news/asco/Gedatolisib_Fact_Sheet_25MAY2018.pdf
15. Functional Assessments of Gynecologic Cancer Models Highlight ..., accessed September 25, 2025, https://www.mdpi.com/2072-6694/16/20/3520
16. Gedatolisib - Celcuity, accessed September 25, 2025, https://www.celcuity.com/gedatolisib/
17. Gedatolisib (PKI-587) | PI3K/mTOR Inhibitor - MedchemExpress.com, accessed September 25, 2025, https://www.medchemexpress.com/PKI-587.html
18. Gedatolisib Shatters Phase 3 Goals and Scales For Breast Cancer Breakthrough, accessed September 25, 2025, https://www.pharmaceuticalonline.com/doc/gedatolisib-shatters-phase-goals-and-scales-for-breast-cancer-breakthrough-0001
19. Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer, accessed September 25, 2025, https://www.cancernetwork.com/view/gedatolisib-combos-improve-pfs-in-advanced-pik3ca-wild-type-breast-cancer
20. Gedatolisib shows superior potency and efficacy versus single-node ..., accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/38839777/
21. Abstract P2-02-07: Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions - AACR Journals, accessed September 25, 2025, https://aacrjournals.org/clincancerres/article/31/12_Supplement/P2-02-07/753539/Abstract-P2-02-07-Different-effects-of-gedatolisib
22. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings - PubMed, accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/34058066/
23. Breast Cancer Not Yet Recruiting Phase 3 Trials for Gedatolisib (DB11896) - DrugBank, accessed September 25, 2025, https://go.drugbank.com/indications/DBCOND0028036/clinical_trials/DB11896?phase=3&status=not_yet_recruiting
24. Clinical Trials Using Gedatolisib - NCI, accessed September 25, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/gedatolisib?pn=1
25. A Phase 3, Open-Label, Randomized, 2 Part Study Comparing Gedatolisib in Combination with Palbociclib & Fulvestrant to SoC Therapies in Patients with HR+ HER2- Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor with Non-Steroidal AI Therapy | Joint Clinical Trials Office, accessed September 25, 2025, https://jcto.weill.cornell.edu/open_clinical_trials/a-phase-3-open-label-randomized-2-part-study-comparing-gedatolisib-in-combination-with-palbociclib-fulvestrant-to-soc-therapies-in-patients-with-hr-her2-advanced-breast-cancer-previously-treated-with-a-cdk46-inhibitor-with-non
26. FDA Accepts New Drug Application for Gedatolisib in PIK3CA Wild-Type Breast Cancer, accessed September 25, 2025, https://www.cancernetwork.com/view/fda-accepts-new-drug-application-for-gedatolisib-in-pik3ca-wild-type-breast-cancer
27. A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1). | Journal of Clinical Oncology - ASCO Publications, accessed September 25, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS1118
28. A Breast Cancer Study 1st line treatment for HR+/HER2 - Celcuity, accessed September 25, 2025, https://www.celcuity.com/our-approach/viktoria-2-2/
29. Gedatolisib Displays Early Efficacy in mCRPC and Pretreated ..., accessed September 25, 2025, https://www.onclive.com/view/gedatolisib-displays-early-efficacy-in-mcrpc-and-pretreated-her2-breast-cancer
30. Study Details | NCT06190899 | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | ClinicalTrials.gov, accessed September 25, 2025, https://clinicaltrials.gov/study/NCT06190899?term=AREA%5BConditionSearch%5D(%22Prostate%20Disease%22)%20AND%20AREA%5BInterventionSearch%5D(%22protein%20kinase%20inhibitors%22)&rank=1
31. A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). | Journal of Clinical Oncology - ASCO Publications, accessed September 25, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS5109
32. Stage IV (Metastatic) Breast Cancer Unknown Status Phase 2 Trials for Gedatolisib (DB11896) - DrugBank, accessed September 25, 2025, https://go.drugbank.com/indications/DBCOND0031631/clinical_trials/DB11896?phase=2&status=unknown_status
33. NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | ClinicalTrials.gov, accessed September 25, 2025, https://clinicaltrials.gov/study/NCT03065062
34. NCT03243331 | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | ClinicalTrials.gov, accessed September 25, 2025, https://clinicaltrials.gov/study/NCT03243331
35. NCT02626507 | Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer | ClinicalTrials.gov, accessed September 25, 2025, https://clinicaltrials.gov/study/NCT02626507
36. NCT01920061 | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | ClinicalTrials.gov, accessed September 25, 2025, https://clinicaltrials.gov/study/NCT01920061
37. Celcuity's Multi-Target PAM Inhibitor Shows Unprecedented Survival Benefit in PIK3CA Wild-Type Advanced Breast Cancer - Applied Clinical Trials, accessed September 25, 2025, https://www.appliedclinicaltrialsonline.com/view/celcuity-multi-target-pam-inhibitor-unprecedented-survival-benefit-pik3ca-wild-type-advanced-breast-cancer
38. Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial - GlobeNewswire, accessed September 25, 2025, https://www.globenewswire.com/news-release/2025/07/28/3122331/0/en/Celcuity-Announces-Clinically-Meaningful-Improvement-in-Both-Progression-Free-Survival-PFS-Primary-Endpoints-from-PIK3CA-Wild-Type-Cohort-of-Phase-3-VIKTORIA-1-Trial.html
39. Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1), accessed September 25, 2025, https://clin.larvol.com/trial-detail/NCT05501886
40. Gedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer | Targeted Oncology, accessed September 25, 2025, https://www.targetedonc.com/view/gedatolisib-shows-impressive-pfs-in-hr-her2-breast-cancer
41. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study - PubMed, accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/38547892/
42. Gedatolisib Shows Encouraging Early Efficacy in mCRPC and HER2+ mBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways, accessed September 25, 2025, https://www.targetedonc.com/view/gedatolisib-shows-encouraging-early-efficacy-in-mcrpc-and-her2-mbc
43. FDA Grants Gedatolisib, a Dual PI3K and mTOR Inhibitor, Fast-Track Review for ER-Positive, HER2-Negative Breast Cancer, accessed September 25, 2025, https://jhoponline.com/issue-archive/2022-issues/february-2022-vol-12-no-1/fda-grants-gedatolisib-a-dual-pi3k-and-mtor-inhibitor-fast-track-review-for-er-positive-her2-negative-breast-cancer
44. FDA Accepts Gedatolisib for Real-Time Review in HR+/HER2– Advanced Breast Cancer, accessed September 25, 2025, https://www.targetedonc.com/view/fda-accepts-gedatolisib-for-real-time-review-in-hr-her2-advanced-breast-cancer
45. Celcuity (CELC) Is Up 7.2% After FDA Accepts Gedatolisib NDA for Advanced Breast Cancer Approval - Sahm, accessed September 25, 2025, https://www.sahmcapital.com/news/content/celcuity-celc-is-up-72-after-fda-accepts-gedatolisib-nda-for-advanced-breast-cancer-approval-2025-09-03
46. Itovebi | European Medicines Agency (EMA), accessed September 25, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/itovebi
47. European Medicines Agency (EMA), accessed September 25, 2025, https://www.ema.europa.eu/en/medicines
48. Truqap | European Medicines Agency (EMA), accessed September 25, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/truqap
49. EMA Recommends Granting a Marketing Authorisation for Inavolisib - ESMO, accessed September 25, 2025, https://www.esmo.org/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-inavolisib
50. Expanded Access Program - Celcuity, accessed September 25, 2025, https://www.celcuity.com/expanded-access-program/
51. Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - FirstWord Pharma, accessed September 25, 2025, https://firstwordpharma.com/story/6094783
52. Our Pipeline - Celcuity, accessed September 25, 2025, https://www.celcuity.com/our-pipeline/
53. celc_ex993 - SEC.gov, accessed September 25, 2025, https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex993.htm
54. Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models - AACR Journals, accessed September 25, 2025, https://aacrjournals.org/cancerres/article/84/9_Supplement/PO1-24-04/744420/Abstract-PO1-24-04-Gedatolisib-a-pan-PI3K-mTOR
55. The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer ..., accessed September 25, 2025, https://ar.iiarjournals.org/content/31/3/849
56. Dual Inhibition Of PI3K and mTOR Shows Preferential Antileukemic Activity In MLL-Rearranged AML | Blood | American Society of Hematology, accessed September 25, 2025, https://ashpublications.org/blood/article/122/21/818/70902/Dual-Inhibition-Of-PI3K-and-mTOR-Shows
57. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor ..., accessed September 25, 2025, https://www.mdpi.com/2072-6694/16/6/1137
58. A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of ..., accessed September 25, 2025, https://www.mdpi.com/1422-0067/24/19/14821